SynthesisArchives of gynecology and obstetrics2024
The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis.
Synthesis in Archives of gynecology and obstetrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis.BMC cancer · 2024Pooled it
- An L1CAM-Positive Fibroblast-Associated Stromal State Is Associated with Reduced T/NK Cytotoxicity Features in Colorectal Cancer.Biomedicines · 2026Article
- Diagnostic accuracy of the droplet digital PCR POLE mutation test in endometrial cancer: comparison with Sanger sequencing and NGS.Journal of gynecologic oncology · 2026Article
- Endometrial Cancer of the Uterine Isthmus: A Cohort Study on Clinicopathological Features and Prognosis.Cancer medicine · 2026Article
- Development of Antibody-Drug Conjugates Targeting L1CAM to Treat Metastatic Cancer.Molecular cancer therapeutics · 2026Article
- Molecular and AI enabled prognostication in endometrial cancer a 2015 to 2024 bibliometric Atlas and critical review.Discover oncology · 2026Article
- Clinical Validation of DNA Methylation Detection in Cervical Exfoliated Cells for Endometrial Cancer in Women with Suspected Lesions.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- L1CAM/CD171 expression in human tumors and its association with tumor phenotype.Acta oncologica (Stockholm, Sweden) · 2025Article
- SAMD4B: a novel prognostic biomarker of endometrial carcinoma.Translational cancer research · 2025Article
- Molecular subtypes and quantitative analysis of PD-L1 and tumor-associated immune cells in uterine carcinosarcoma.Journal of gynecologic oncology · 2025Article
- UnveilingTranslational cancer research · 2025Article
- Construction of a novel ferroptosis-related long non-coding RNAs model for predicting prognosis and tumor immune microenvironment in endometrial cancer.Annals of translational medicine · 2025Article
- Article
- Impact of sirtuin‑1 expression on progression‑free survival in non‑endometrioid endometrial cancer: A retrospective cohort study.Oncology letters · 2025Article
- Proteomic Changes Associated With Endogenous FBXW7 Mutations in Moderately Differentiated Endometrial Cancer Cells Include Increased TROP2 and Galectin-3 Levels.Cancer medicine · 2025Article
- Does FIGO 2023 meet clinical needs? An analysis of challenges and limitations.Przeglad menopauzalny = Menopause review · 2025Review
- Significance of Gelsolin Superfamily Genes in Diagnosis, Prognosis and Immune Microenvironment Regulation for Endometrial Cancer.Cancer medicine · 2025Article
- Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma.Frontiers in cell and developmental biology · 2025Article
- The Value of Integrating Hormone Receptors into Immunohistochemistry-Based Simplified Molecular Classification in Endometrial Cancer.Cancer management and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMolecular and genomic profiling in endometrial cancer is increasing popularity. L1 cell adhesion molecule (L1CAM) is frequently mutated in endometrial cancer. In this paper, we aim to evaluate the prognostic role of L1CAM in patients with stage I endometrial cancer.
methodsWe performed a systematic review and meta-analysis searching in PubMed (MEDLINE), EMBASE, and Web of Science database to identify studies reporting the expression of L1CAM in endometrial cancer. The primary endpoint measure was to assess and evaluate the impact of L1CAM on survival outcomes. This study was performed according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) statement.
resultsFive studies were included. The pooled results suggested that L1CAM expression influences survival outcomes in stage I endometrial cancer. High L1CAM expression correlated with worse disease-free survival (HR 4.11, 95% CI 1.02-16.59, p = 0.047) and overall survival (HR 3.62, 95% CI 1.32-9.31, p = 0.012). High L1CAM level was also associated with a more aggressive FIGO grade and with older age.
conclusionThis systematic review supported that L1CAM have a prognostic role in stage I endometrial cancer, thus providing a potential useful tool for tailoring the need of adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.